The Fukushima Daiichi nuclear power plant’s radiation levels have significantly dropped since the cataclysmic meltdown 14 ...

AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s ...

Representatives from politics, business and science have signed a Memorandum of Understanding (MOU) to establish a ...

8316.T Sumitomo Mitsui Financial Group, Inc.

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

AstraZeneca and Daiichi Sankyo have claimed FDA approval for a second antibody-drug conjugate (ADC) for breast cancer, hoping to build on the success of a partnership that already spawned a ...

The top diplomats of China, South Korea and Japan will meet in Tokyo for talks this weekend, the three East Asian countries ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Fukushima Daiichi nuclear power plant's radiation levels have significantly dropped since the meltdown in Japan 14 years ...